Clinical and Translational Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain
ConclusionsThe potential of Precision Medicine has not been fulfilled in Spain. While several regional initiatives are in place, a national plan or strategy around Precision Medicine and use of biomarkers is lacking. In a general context of rapid progress at a global and European level, including the 2021 Europe ’s Beating Cancer Plan, it is time to define and implement a National Plan to make the promise come true. While some comparable countries within Europe – such as the UK or France – are mature enough to adopt such strategies, in Spain there is still a long way to go. We consider tha t the differ...
Source: Clinical and Translational Oncology - January 11, 2024 Category: Cancer & Oncology Source Type: research

Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer
ConclusionCDKN2A upregulation extensively enhances the carcinogenesis and progression of SCLC. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - January 11, 2024 Category: Cancer & Oncology Source Type: research

Using Vision Transformer for high robustness and generalization in predicting EGFR mutation status in lung adenocarcinoma
ConclusionsThe ViT model demonstrates a high level of accuracy in predicting the EGFR mutation status of lung adenocarcinoma patients. Moreover, with the aid of attention maps, the model can assist clinicians in making informed clinical decisions. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - January 9, 2024 Category: Cancer & Oncology Source Type: research

Depression promotes breast cancer progression by regulating amino acid neurotransmitter metabolism and gut microbial disturbance
ConclusionDepression promoted the progression of BC by modulating the abundance ofs_Lachnospiraceae ands_Bacteroides_caecimuris, which affected the metabolism of monoamine neurotransmitters in the brain and AA in the blood. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - January 9, 2024 Category: Cancer & Oncology Source Type: research

Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1
ConclusionThe TMB > = 16 shows significantly associated with optimal ICIP treatment outcomes, including higher patient survival rates, delayed disease progression, and significant clinical benefits. These results present the potential of TMB as a promising biomarker candidate for NSCLC patients undergoing ICIP treatment. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - January 8, 2024 Category: Cancer & Oncology Source Type: research

Primary versus acquired epidermal growth factor receptor Thr790Met mutant non-small cell lung cancer: clinical features and prognoses
ConclusionPatients with primary T790M have unique molecular features and had worse prognosis compared with acquired T790M. Resistance to third-generation EGFR-TKIs seems to be associated with the presence of EGFR co-mutations. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - January 8, 2024 Category: Cancer & Oncology Source Type: research

The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients
ConclusionBoth pre- and post-treatment systemic immune-inflammatory markers have a significant predictive role in achieving pCR after NAT in breast cancer patients. Indeed, it is possible that post-treatment markers have stronger predictive ability compared to pre-treatment markers. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - January 8, 2024 Category: Cancer & Oncology Source Type: research

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer
ConclusionOur results provide evidence on the prognostic value ofSTK11,KEAP1, andCDKN2A/B mutations in patients with aNSCLC. Further research is required to better understand the implications of these findings on patient management and future trial design and treatment selection. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - January 6, 2024 Category: Cancer & Oncology Source Type: research